DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
Status:
RECRUITING
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
This study will treat patients with CLL/SLL whose disease comes back or is not responding to prior therapy, or if they can not bear side effects of the prior treatment. This study will assess the anti-tumor activity of DZD8586 as monotherapy. It will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body.